Restless legs syndrome: Manifestations, treatment and dental implications

Journal of the American Dental Association

Volumn 137, Issue 6, 2006, Pages 755-761

  Friedlander, Arthur H ^a,b,c   Mahler, Michael E ^a,d   Yagiela, John A ^c,d  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UCLA SCHOOL OF DENTISTRY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dentistry; Neurological movement disorders; Restless legs syndrome

Indexed keywords

EID: 33745751397     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2006.0287     Document Type: Article

References (44)

1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations and epidemiology-a report from the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health. Sleep Med 2003;4(2):101-19.
2. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164(2):196-202.
3. Hening WA. Subjective and objective criteria in the diagnosis of the restless legs syndrome. Sleep Med 2004;5:285-92.
4. Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 2004;24:249-59.
5. Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med 2004;5:305-8.
6. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5:385-91.
7. Gosselin N, Lanfranchi P, Michaud M, et al. Age and gender effects on heart rate activation associated with periodic leg movements in patients with restless legs syndrome. Clin Neurophysiol 2003;114:2188-95.
8. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5:237-46.
9. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study-memory and morbidity in Augsburg elderly. Neurology 2000;54:1064-8.
10. Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001;16:577-9.
11. Kageyama T, Kabuto M, Nitta H, et al. Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin Neurosci 2000;54:296-8.
12. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000;160:2137-41.
13. Zucconi M, Ferini-Strambi L. Epidemiology and clinical findings of restless legs syndrome. Sleep Med 2004;5:293-9.
14. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004;26:925-35.
15. Winkelmann J, Muller-Myhsok B, Wittchen HU, et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002;52:297-302.
16. Chen S, Ondo WG, Rao S, Li L, Chen Q, Wang Q. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004;74:876-85.
17. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000;55:1404-6.
18. Earley CJ, Allen RP, Beard JL, Connor JR. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000;62:623-8.
19. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-9.
20. Ferreri F, Rossini PM. Neurophysiological investigations in restless legs syndrome and other disorders of movement during sleep. Sleep Med 2004;5:397-9.
21. Rama AN, Kushida CA. Restless legs syndrome and periodic limb movement disorder. Med Clin North Am 2004;88:653-67.
22. Littner MR, Kushida C, Anderson WM, et al; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:557-9.
23. Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61:1393-7.
24. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59 (10):1573-9.
25. Schapira AH. Restless legs syndrome: an update on treatment options. Drugs 2004;64(2):149-58.
26. Silber MH, Ehrenberg BL, Allen RP, et al; Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for management of restless legs syndrome (published correction appears in Mayo Clin Proc 2004;79:1341). Mayo Clin Proc 2004;79:916-22.
27. Physicians' desk reference. 59th ed. Montvale, N.J.: Medical Economics; 2005.
28. McEvoy GK, ed. AHFS drug information 2005. Bethesda, Md.: American Society of Health-System Pharmacists; 2005.
29. Wynn RL, Meiller TF, Crossley HL, eds. Drug information handbook for dentistry. 9th ed. Hudson, Ohio: Lexi-Comp; 2003.
30. Byrne BE. Oral manifestations of systemic agents. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003;504-50.
31. Winocur E, Gavish A, Voikovitch M, Emodi-Perlman A, Eli I. Drugs and bruxism: a critical review. J Orofac Pain 2003;17(2):99-111.
32. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994;17:739-43.
33. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of pergolide-associated heart disease. Mayo Clin Proc 2003;78:730-1.
34. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-83.
35. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-62.
36. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JADA 1997;128:1142-51.
37. Scully C, Roberts G, Shotts R. The mouth in heart disease. Practitioner 2001;245:432-7.
38. Carmona IT, Diz Dios P, Scully C. An update on the controversies in bacterial endocarditis of oral origin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:660-70.
39. Pallasch TJ, Gage TW, Taubert KA. The 1997 prevention of bacterial endocarditis recommendations by the American Heart Association: questions and answers. J Calif Dent Assoc 1999;27:393-9.
40. Mask AG Jr. Medical management of the patient with cardiovascular disease. Periodontol 2000 2000;23(June):136-41.
41. Ganzberg. S. Analgesics: opioids and nonopioids. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003:77-103.
42. Ganzberg S. Neurologic drugs. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003:366-81.
43. Ganzberg S. Psychoactive drugs. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003:382-411.
44. Restless Legs Syndrome Foundation. Available at: "www.rls.org". Accessed Jan 17., 2005.